These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16310654)

  • 1. The genetics of malignant hyperthermia.
    Brandom BW
    Anesthesiol Clin North Am; 2005 Dec; 23(4):615-9, viii. PubMed ID: 16310654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.
    Riazi S; Kraeva N; Hopkins PM
    Anesthesiology; 2018 Jan; 128(1):168-180. PubMed ID: 28902675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of malignant hyperthermia.
    Brandom BW
    ScientificWorldJournal; 2006 Dec; 6():1722-30. PubMed ID: 17195870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.
    Riazi S; Kraeva N; Muldoon SM; Dowling J; Ho C; Petre MA; Parness J; Dirksen RT; Rosenberg H
    Can J Anaesth; 2014 Nov; 61(11):1040-9. PubMed ID: 25189431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital ptosis, scoliosis, and malignant hyperthermia susceptibility in siblings with recessive RYR1 mutations.
    AlBakri A; Karaoui M; Alkuraya FS; Khan AO
    J AAPOS; 2015 Dec; 19(6):577-9. PubMed ID: 26691049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.
    Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V
    Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant hyperthermia.
    Urwyler A; Halsall PJ; Mueller C; Robinson R
    Acta Anaesthesiol Scand; 2003 Apr; 47(4):492; author reply 493. PubMed ID: 12694155
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
    Vukcevic M; Broman M; Islander G; Bodelsson M; Ranklev-Twetman E; Müller CR; Treves S
    Anesth Analg; 2010 Jul; 111(1):185-90. PubMed ID: 20142353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
    Ta TA; Pessah IN
    Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive diagnosis of malignant hyperthermia susceptibility by genetic testing: A case report.
    Basile E; McGrath K; Jones K; Apostolov BD; Kahana M
    Paediatr Anaesth; 2023 Oct; 33(10):868-869. PubMed ID: 37357724
    [No Abstract]   [Full Text] [Related]  

  • 11. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia with R316C RYR1 novel missense mutation.
    Kiatchai T; Ratanaphruthakul P; Poopipatpab S
    Paediatr Anaesth; 2019 Sep; 29(9):968-969. PubMed ID: 31304636
    [No Abstract]   [Full Text] [Related]  

  • 13. RYR1 variant c.38T>G, p.Leu13Arg causes hypersensitivity of the ryanodine receptor-1 and is pathogenic for malignant hyperthermia.
    van den Bersselaar LR; Greven T; Bulger T; Voermans NC; van Petegem F; Schiemann AH; Parker R; Burling SM; Jungbluth H; Stowell KM; Kamsteeg EJ; Snoeck MMJ
    Br J Anaesth; 2021 Aug; 127(2):e63-e65. PubMed ID: 34127251
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignant hyperthermia.
    Bouchama A; Hussain S
    Lancet; 1998 Nov; 352(9142):1785. PubMed ID: 9848381
    [No Abstract]   [Full Text] [Related]  

  • 15. Increasing the number of diagnostic mutations in malignant hyperthermia.
    Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
    Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population.
    Kraeva N; Riazi S; Loke J; Frodis W; Crossan ML; Nolan K; Kraev A; Maclennan DH
    Can J Anaesth; 2011 Jun; 58(6):504-13. PubMed ID: 21455645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Core myopathies and malignant hyperthermia susceptibility: a review.
    Brislin RP; Theroux MC
    Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal diagnosis of malignant hyperthermia susceptibility.
    Girard T; Jöhr M; Schaefer C; Urwyler A
    Anesthesiology; 2006 Jun; 104(6):1353-4. PubMed ID: 16732128
    [No Abstract]   [Full Text] [Related]  

  • 19. Continued progress in understanding the molecular genetics of malignant hyperthermia.
    Rosenberg H
    Can J Anaesth; 2011 Jun; 58(6):489-93. PubMed ID: 21455644
    [No Abstract]   [Full Text] [Related]  

  • 20. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
    MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
    J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.